About Stoke Therapeutics
Stoke Therapeutics (NASDAQ:STOK) is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with its proprietary RNA-based approach, TANGO (Targeted Augmentation of Nuclear Gene Output). The company aims to pioneer transformative therapies to improve the lives of individuals suffering from diseases caused by a single genetic mutation, such as Dravet syndrome, a severe form of epilepsy. Stoke Therapeutics is dedicated to advancing its lead candidate, STK-001, through clinical development for the treatment of Dravet syndrome, as well as expanding its pipeline to address other genetic conditions. The company's objectives include delivering breakthrough treatments to patients in need and establishing itself as a leader in genetic medicine by leveraging its TANGO technology to address currently untreatable conditions.
Snapshot
Operations
Products and/or services of Stoke Therapeutics
- STK-001, a treatment targeting Dravet syndrome, aiming to address the underlying cause of this severe form of epilepsy.
- STK-002 focuses on addressing the genetic cause of autosomal dominant optic atrophy.
- Research into TANGO (Targeted Augmentation of Nuclear Gene Output) technology for correcting protein imbalances in genetic diseases.
- Development of therapies for amyotrophic lateral sclerosis (ALS) through genetic modulation.
- Initiatives in creating treatments for Rett Syndrome, emphasizing advancements in neurological disorder therapies.
- Pursuit of novel strategies in combating genetic forms of epilepsy, leveraging cutting-edge RNA editing techniques.
Stoke Therapeutics executive team
- Mr. Ian F. Smith A.C.A., C.P.A.CEO & Director
- Dr. Adrian R. Krainer Ph.D.Co-Founder & Independent Director
- Mr. Thomas Edward LeggettChief Financial Officer
- Dr. Edward M. Kaye M.D., Ph.D.Advisor & Director
- Dr. Barry S. Ticho FACC, M.D., Ph.D.Chief Medical Officer
- Ms. Isabel Aznarez Ph.D.Co-Founder, Head of Research & Senior VP
- Doug SnowDirector of Communications & Investor Relations
- Mr. Jonathan Allan J.D.Corporate Secretary & General Counsel
- Ms. Sara Den BestenChief People Officer
- Ms. Dawn KalmarChief of Corporate Affairs & Strategic Partnerships